{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:09:23Z","timestamp":1791324563690,"version":"4.3.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04080-z","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:24:11Z","timestamp":1761215051000},"page":"4381-4392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SEOM\u2013GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7541-9832","authenticated-orcid":false,"given":"Josep","family":"Gum\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Palaz\u00f3n-Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sequero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"G\u00f3mez-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Mart\u00ednez-Banaclocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"4080_CR1","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s12094-023-03206-5","volume":"25","author":"J Gum\u00e0","year":"2023","unstructured":"Gum\u00e0 J, Palaz\u00f3n-Carri\u00f3n N, Rueda-Dom\u00ednguez A, Sequero S, Calvo V, Garc\u00eda-Arroyo R, et al. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022). Clin Transl Oncol. 2023;25:2749\u201358. https:\/\/doi.org\/10.1007\/s12094-023-03206-5.","journal-title":"Clin Transl Oncol"},{"key":"4080_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1086\/656735","volume":"51","author":"AR Khan","year":"2010","unstructured":"Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147\u201356. https:\/\/doi.org\/10.1086\/656735.","journal-title":"Clin Infect Dis"},{"key":"4080_CR3","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a, 2022. 2022. https:\/\/redecan.org\/storage\/documents\/873877e1-af1b-43fe-8d97-0ee1434fe261.pdf. Accessed 30 Jul 2025."},{"key":"4080_CR4","doi-asserted-by":"publisher","unstructured":"Marcos-Gragera R, Poll\u00e1n M, Chirlaque MD, Gum\u00e0 J, Sanchez MJ, Garau I. Attenuation of the epidemic increase in non-Hodgkin\u2019s lymphomas in Spain. Ann Oncol. 2010;21 Suppl 3:iii90\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdq088.","DOI":"10.1093\/annonc\/mdq088"},{"key":"4080_CR5","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a, 2024 [in Spanish]. 2024. https:\/\/redecan.org\/storage\/documents\/09a96a55-6939-419d-ba3e-202d7ae76e1d.pdf. Accessed 30 Jul 2025."},{"key":"4080_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12094-012-0813-3","volume":"14","author":"M Provencio","year":"2012","unstructured":"Provencio M, Sab\u00edn P, Codina J, Rueda A, Llanos M, Gum\u00e0 J, et al. Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol. 2012;14:386\u201390. https:\/\/doi.org\/10.1007\/s12094-012-0813-3.","journal-title":"Clin Transl Oncol"},{"key":"4080_CR7","unstructured":"Marcos-Gragera R, Ameijide A, Solans M, Sanvisens A, Castro Vd, Chirlaque MD, et al. Incidence and trends of haematological malignancies in Spain, 2002\u20132013. Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). 2021. https:\/\/redecan.org\/storage\/documents\/61ad123d-aa03-43db-b96a-b4e22d1837fb.pdf. Accessed 30 Jul 2025."},{"key":"4080_CR8","doi-asserted-by":"publisher","first-page":"1046307","DOI":"10.3389\/fonc.2022.1046307","volume":"12","author":"C Pla","year":"2022","unstructured":"Pla C, Solans M, Ameijide A, Sanvisens A, Carulla M, Rojas MD, et al. Incidence and survival of lymphoid neoplasms in Spain, 2002\u20132013: a population-based study from the Spanish network of cancer registries (REDECAN). Front Oncol. 2022;12:1046307. https:\/\/doi.org\/10.3389\/fonc.2022.1046307.","journal-title":"Front Oncol"},{"key":"4080_CR9","unstructured":"Moreno SM, Villanueva MM, Fraga M, Garc\u00eda JF, Villar JL, Mart\u00ednez A, et al. Recomendaciones para el estudio histopatologico, inmunohistoquimico, citogen\u00e9tico y molecular e informe diagnostico de los procesos neopl\u00e1sicos linfoides. Consenso SEAP-SEHH-GOTEL. In: Sastre ER, editor. Libro Blanco de la Anatomia Patologica en Espa\u00f1a, 7th ed. SEAP-IAP, 2021."},{"key":"4080_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/00000478-200404000-00005","volume":"28","author":"CC Chang","year":"2004","unstructured":"Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28:464\u201370. https:\/\/doi.org\/10.1097\/00000478-200404000-00005.","journal-title":"Am J Surg Pathol"},{"key":"4080_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417\u201329. https:\/\/doi.org\/10.1056\/NEJMra0807082.","journal-title":"N Engl J Med"},{"key":"4080_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006.","journal-title":"Pathology"},{"key":"4080_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311. https:\/\/doi.org\/10.1038\/35000501.","journal-title":"Nature"},{"key":"4080_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382. https:\/\/doi.org\/10.1182\/blood-2003-05-1545.","journal-title":"Blood"},{"key":"4080_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-68.e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015.","journal-title":"Cancer Cell"},{"key":"4080_CR16","unstructured":"World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors: International Agency for Research on Cancer, World Health Organization; 2017."},{"key":"4080_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. https:\/\/doi.org\/10.1200\/jco.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"4080_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00259-013-2623-4","volume":"41","author":"HJ Adams","year":"2014","unstructured":"Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Nievelstein RA. FDG PET\/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41:565\u201374. https:\/\/doi.org\/10.1007\/s00259-013-2623-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4080_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejm199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA, Harrington DP, Anderson JR, Armitage JO, Brittinger G, Cabanillas F, et al. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394. https:\/\/doi.org\/10.1056\/nejm199309303291402.","journal-title":"N Engl J Med"},{"key":"4080_CR20","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/jco.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373\u201380. https:\/\/doi.org\/10.1200\/jco.2009.26.2493.","journal-title":"J Clin Oncol"},{"key":"4080_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/nejm199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339:21\u20136. https:\/\/doi.org\/10.1056\/nejm199807023390104.","journal-title":"N Engl J Med"},{"key":"4080_CR22","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1200\/jco.2004.05.926","volume":"22","author":"TP Miller","year":"2004","unstructured":"Miller TP. The limits of limited stage lymphoma. J Clin Oncol. 2004;22:2982\u20134. https:\/\/doi.org\/10.1200\/jco.2004.05.926.","journal-title":"J Clin Oncol"},{"key":"4080_CR23","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/s0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(19)33008-9.","journal-title":"Lancet"},{"key":"4080_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131:174\u201381. https:\/\/doi.org\/10.1182\/blood-2017-07-793984.","journal-title":"Blood"},{"key":"4080_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/10428194.2014.930853","volume":"56","author":"OO Odejide","year":"2015","unstructured":"Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015;56:716\u201324. https:\/\/doi.org\/10.3109\/10428194.2014.930853.","journal-title":"Leuk Lymphoma"},{"key":"4080_CR26","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/jco.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024\u201334. https:\/\/doi.org\/10.1200\/jco.2017.76.8093.","journal-title":"J Clin Oncol"},{"key":"4080_CR27","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/jco.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38:3003\u201311. https:\/\/doi.org\/10.1200\/jco.20.00999.","journal-title":"J Clin Oncol"},{"key":"4080_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(11)70235-2.","journal-title":"Lancet Oncol"},{"key":"4080_CR29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G, Murawski N, Ziepert M, Fleckenstein J, P\u00f6schel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112\u20138. https:\/\/doi.org\/10.1200\/jco.2013.51.4505.","journal-title":"J Clin Oncol"},{"key":"4080_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"key":"4080_CR31","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/jco.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u201326. https:\/\/doi.org\/10.1200\/jco.2005.09.131.","journal-title":"J Clin Oncol"},{"key":"4080_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316. https:\/\/doi.org\/10.1016\/s1470-2045(08)70002-0.","journal-title":"Lancet Oncol"},{"key":"4080_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(13)60313-x","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817\u201326. https:\/\/doi.org\/10.1016\/s0140-6736(13)60313-x.","journal-title":"Lancet"},{"key":"4080_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s1470-2045(13)70122-0","volume":"14","author":"R Delarue","year":"2013","unstructured":"Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525\u201333. https:\/\/doi.org\/10.1016\/s1470-2045(13)70122-0.","journal-title":"Lancet Oncol"},{"key":"4080_CR35","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/s0140-6736(11)61040-4","volume":"378","author":"C R\u00e9cher","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, Molina TJ, Ferm\u00e9 C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858\u201367. https:\/\/doi.org\/10.1016\/s0140-6736(11)61040-4.","journal-title":"Lancet"},{"key":"4080_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.13273","volume":"169","author":"N Purroy","year":"2015","unstructured":"Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 2015;169:188\u201398. https:\/\/doi.org\/10.1111\/bjh.13273.","journal-title":"Br J Haematol"},{"key":"4080_CR37","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/jco.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303. J Clin Oncol. 2019;37:1790\u20139. https:\/\/doi.org\/10.1200\/jco.18.01994.","journal-title":"J Clin Oncol"},{"key":"4080_CR38","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/jco.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529\u201337. https:\/\/doi.org\/10.1200\/jco.2017.73.3402.","journal-title":"J Clin Oncol"},{"key":"4080_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"key":"4080_CR40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/s1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(18)30935-5.","journal-title":"Lancet Oncol"},{"key":"4080_CR41","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/jco.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285\u201395. https:\/\/doi.org\/10.1200\/jco.18.02403.","journal-title":"J Clin Oncol"},{"key":"4080_CR42","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Ill\u00e9s \u00c1, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600\u20139. https:\/\/doi.org\/10.1182\/blood.2020006578.","journal-title":"Blood"},{"key":"4080_CR43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/jco.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:1317\u201328. https:\/\/doi.org\/10.1200\/jco.20.01366.","journal-title":"J Clin Oncol"},{"key":"4080_CR44","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/jco.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121\u20137. https:\/\/doi.org\/10.1200\/jco.2005.05.1003.","journal-title":"J Clin Oncol"},{"key":"4080_CR45","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1200\/jco.2015.65.7171","volume":"34","author":"M Crump","year":"2016","unstructured":"Crump M, Lepp\u00e4 S, Fayad L, Lee JJ, Di Rocco A, Ogura M, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2016;34:2484\u201392. https:\/\/doi.org\/10.1200\/jco.2015.65.7171.","journal-title":"J Clin Oncol"},{"key":"4080_CR46","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/annonc\/mdx764","volume":"29","author":"TE Witzig","year":"2018","unstructured":"Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018;29:707\u201314. https:\/\/doi.org\/10.1093\/annonc\/mdx764.","journal-title":"Ann Oncol"},{"key":"4080_CR47","doi-asserted-by":"publisher","unstructured":"Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35:2473\u201381. https:\/\/doi.org\/10.1200\/jco.2017.72.6984.","DOI":"10.1200\/jco.2017.72.6984"},{"key":"4080_CR48","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/jco.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390. https:\/\/doi.org\/10.1200\/jco.2010.28.1618.","journal-title":"J Clin Oncol"},{"key":"4080_CR49","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/jco.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490\u20136. https:\/\/doi.org\/10.1200\/jco.2013.53.9593.","journal-title":"J Clin Oncol"},{"key":"4080_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"key":"4080_CR51","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386:629\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2116596.","journal-title":"N Engl J Med"},{"key":"4080_CR52","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6.","journal-title":"Lancet"},{"key":"4080_CR53","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315. https:\/\/doi.org\/10.1182\/blood.2022018893.","journal-title":"Blood"},{"key":"4080_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00399","author":"M Kamdar","year":"2025","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III transform study. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/jco-25-00399.","journal-title":"J Clin Oncol"},{"key":"4080_CR55","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/jco.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119\u201328. https:\/\/doi.org\/10.1200\/jco.19.02104.","journal-title":"J Clin Oncol"},{"key":"4080_CR56","doi-asserted-by":"publisher","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther. 2022;28:581.e1\u2013.e8. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.026.","DOI":"10.1016\/j.jtct.2022.05.026"},{"key":"4080_CR57","unstructured":"US Food and Drug Administration (FDA). FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma. Accessed 22 Jul 2025."},{"key":"4080_CR58","unstructured":"European Medicines Agency (EMA). Yescarta: EPAR \u2013 Product Information. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yescarta-epar-product-information_en.pdf. Accessed 20 Jul 2025."},{"key":"4080_CR59","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/jco.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155\u201365. https:\/\/doi.org\/10.1200\/jco.19.00172.","journal-title":"J Clin Oncol"},{"key":"4080_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/s1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978\u201388. https:\/\/doi.org\/10.1016\/s1470-2045(20)30225-4.","journal-title":"Lancet Oncol"},{"key":"4080_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"key":"4080_CR62","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0.","journal-title":"Lancet"},{"key":"4080_CR63","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/s1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"key":"4080_CR64","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653\u201362. https:\/\/doi.org\/10.1038\/s41375-024-02410-8.","journal-title":"Leukemia"},{"key":"4080_CR65","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"NL Bartlett","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7:4926\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2022009260.","journal-title":"Blood Adv"},{"key":"4080_CR66","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/jco.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40:481\u201391. https:\/\/doi.org\/10.1200\/jco.21.00931.","journal-title":"J Clin Oncol"},{"key":"4080_CR67","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1200\/jco.23.02329","volume":"42","author":"LE Budde","year":"2024","unstructured":"Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-hodgkin lymphomas: extended follow-up of a phase I\/II study. J Clin Oncol. 2024;42:2250\u20136. https:\/\/doi.org\/10.1200\/jco.23.02329.","journal-title":"J Clin Oncol"},{"key":"4080_CR68","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Ja\u017cd\u017cewska E, Poon LM, et al. Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025;6:528\u201339. https:\/\/doi.org\/10.1038\/s43018-025-00921-6.","journal-title":"Nat Cancer"},{"key":"4080_CR69","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"4080_CR70","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/jco.2014.55.7561","volume":"32","author":"CA Thompson","year":"2014","unstructured":"Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32:3506\u201312. https:\/\/doi.org\/10.1200\/jco.2014.55.7561.","journal-title":"J Clin Oncol"},{"key":"4080_CR71","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1200\/jco.2015.62.0229","volume":"33","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Jakobsen LH, Hutchings M, de Nully BP, Nilsson-Ehle H, Sz\u00e9kely E, et al. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol. 2015;33:3993\u20138. https:\/\/doi.org\/10.1200\/jco.2015.62.0229.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04080-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04080-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04080-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:28:39Z","timestamp":1763562519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04080-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4080"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04080-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JG has attended an advisory board for Incyte Biosciences and Kite-Gilead and has received other fees from Roche. ARD has received speaker fees and has attended an advisory board for Roche, BMS, MSD, Takeda, Merck, and Gilead. VC has attended an advisory board for Roche, BMS, AstraZeneca, and Boehringer Ingelheim; has received personal fees from Roche, BMS, MSD, AstraZeneca, Takeda, Lilly, and Boehringer Ingelheim; and has received speaker fees from BMS, MSD, AstraZeneca, Takeda, Pfizer, and Boehringer Ingelheim. ML has attended an advisory board for Incyte and has received speaker fees from Roche. MP has received speaker fees and has attended an advisory board for Roche and Takeda, and has attended an advisory board for Incyte. NPC, SS, RGA, JGC, and NMB declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}]}}